地西他滨诱导的积液。 - Suppr

Suppr

超能文献

Decitabine-induced effusions.

作者信息

Chen Chih-Cheng, Gau Jyh-Pyng, You Jie-Yu, Lu Chang-Hsien, Chan Chung-Huang Hubert, Lin Jen-Tsun, Lee Kuan-Der

出版信息

Leuk Res. 2009 Sep;33(9):e150-1. doi: 10.1016/j.leukres.2008.11.028. Epub 2009 Jan 20.

DOI:10.1016/j.leukres.2008.11.028

PMID:19157543

Abstract

摘要

相似文献

Decitabine-induced effusions.

Leuk Res. 2009 Sep;33(9):e150-1. doi: 10.1016/j.leukres.2008.11.028. Epub 2009 Jan 20.

Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report.

J Oncol Pharm Pract. 2019 Jul;25(5):1248-1252. doi: 10.1177/1078155218784762. Epub 2018 Jun 22.

Decitabine (Dacogen) for myelodysplastic syndromes.

Med Lett Drugs Ther. 2006 Nov 6;48(1247):91-2.

[Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes].

Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):173-5. doi: 10.3760/cma.j.issn.0253-2727.2014.02.026.

Recent experience with decitabine in MDS.

Clin Adv Hematol Oncol. 2007 Feb;5(2):140.

[The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].

Zhonghua Xue Ye Xue Za Zhi. 2011 Nov;32(11):789-91.

Decitabine treatment of patients with higher-risk myelodysplastic syndromes.

Leuk Res. 2009 Dec;33 Suppl 2:S12-7. doi: 10.1016/S0145-2126(09)70228-0.

Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.

Leuk Res. 2011 Apr;35(4):499-503. doi: 10.1016/j.leukres.2010.07.006. Epub 2010 Jul 31.

[Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):573.

A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.

J Med Econ. 2012;15(1):145-54. doi: 10.3111/13696998.2011.631067. Epub 2011 Nov 4.

引用本文的文献

Azacitidine-induced myopericarditis in acute myeloid leukemia.

Proc (Bayl Univ Med Cent). 2022 Aug 18;35(6):849-851. doi: 10.1080/08998280.2022.2111642. eCollection 2022.

Comprehensive review of cardiovascular toxicity of drugs and related agents.

Med Res Rev. 2018 Jul;38(4):1332-1403. doi: 10.1002/med.21476. Epub 2018 Jan 5.

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

Onco Targets Ther. 2010 Jun 24;3:1-13. doi: 10.2147/ott.s7222.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Decitabine-induced effusions.

作者信息

Chen Chih-Cheng, Gau Jyh-Pyng, You Jie-Yu, Lu Chang-Hsien, Chan Chung-Huang Hubert, Lin Jen-Tsun, Lee Kuan-Der

出版信息

Leuk Res. 2009 Sep;33(9):e150-1. doi: 10.1016/j.leukres.2008.11.028. Epub 2009 Jan 20.

DOI:10.1016/j.leukres.2008.11.028

PMID:19157543

Abstract

摘要

相似文献

Decitabine-induced effusions.

Leuk Res. 2009 Sep;33(9):e150-1. doi: 10.1016/j.leukres.2008.11.028. Epub 2009 Jan 20.

Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report.

J Oncol Pharm Pract. 2019 Jul;25(5):1248-1252. doi: 10.1177/1078155218784762. Epub 2018 Jun 22.

Decitabine (Dacogen) for myelodysplastic syndromes.

Med Lett Drugs Ther. 2006 Nov 6;48(1247):91-2.

[Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes].

Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):173-5. doi: 10.3760/cma.j.issn.0253-2727.2014.02.026.

Recent experience with decitabine in MDS.

Clin Adv Hematol Oncol. 2007 Feb;5(2):140.

[The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].

Zhonghua Xue Ye Xue Za Zhi. 2011 Nov;32(11):789-91.

Decitabine treatment of patients with higher-risk myelodysplastic syndromes.

Leuk Res. 2009 Dec;33 Suppl 2:S12-7. doi: 10.1016/S0145-2126(09)70228-0.

Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.

Leuk Res. 2011 Apr;35(4):499-503. doi: 10.1016/j.leukres.2010.07.006. Epub 2010 Jul 31.

[Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):573.

A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.

J Med Econ. 2012;15(1):145-54. doi: 10.3111/13696998.2011.631067. Epub 2011 Nov 4.

引用本文的文献

Azacitidine-induced myopericarditis in acute myeloid leukemia.

Proc (Bayl Univ Med Cent). 2022 Aug 18;35(6):849-851. doi: 10.1080/08998280.2022.2111642. eCollection 2022.

Comprehensive review of cardiovascular toxicity of drugs and related agents.

Med Res Rev. 2018 Jul;38(4):1332-1403. doi: 10.1002/med.21476. Epub 2018 Jan 5.

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

Onco Targets Ther. 2010 Jun 24;3:1-13. doi: 10.2147/ott.s7222.